Monoclonal antibodies against the epidermal growth factor receptor, such as cetuximab, have shown benefit in KRAS and, KRAS and NRAS (RAS), wild‐type advanced colorectal cancer (CRC) when either used as a monotherapy1, 2 or in combination with chemotherapy.3, 4, 5. The gene discussed is KRAS; the disease is colorectal carcinoma.